Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MK-4166 Monotherapy and with Pembrolizumab
NCT02132754Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2014
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of MK-4166 in solid tumor and Malignant Melanoma (MM) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Dose-Limiting Toxicities, Number of Participants Experiencing Adverse Events and 1 more. Started Jun 2014; status: completed.
02
Drugs
MK-4166
03
Conditions
solid tumorMalignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02132754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132754.